Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can GSK’s Blenrep Make A Comeback After Beating Darzalex? Eye Toxicity Concerns Remain

Executive Summary

GSK will talk to regulators about bringing Blenrep back in earlier-stage myeloma patients, likely arguing that its convenience is greater than for CAR-T and carries a lower infection risk than bispecifics.

You may also be interested in...



New RUBY Results Boost GSK's Blockbuster Bid For Jemperli

The company’s PD-1 inhibitor Jemperli plus GSK's own PARP Zejula has scored a win in a late-stage endometrial cancer trial that could lead to a key label expansion.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: CAR-Ts and malignancies; comeback for GSK’s Blenrep?; Novartis’s pipeline cull; FGF21 analogs in NASH; and a call to action from the Scrip Awards Lifetime Achievement winner.

GSK’s Blenrep Hit By Trial Failure, Raising Questions About Its Future In The Myeloma Market

The DREAMM-3 study was meant to be a confirmatory study for Blenrep, and its failure raises concerns over its use in earlier lines of therapy and the possibility that it could be removed from the market.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel